Antibiotic Prophylaxis for Transrectal Prostate Biopsy

Condition(s) targeted: Infection

Intervention: Ciprofloxacin (Drug); trimethoprim-sulfamethoxazole (Drug); cefuroxime (Drug); ceftriaxone (Drug); gentamicin (Drug); amikacin (Drug); aztreonam (Drug); imipenem (Drug); ceftriaxone (Drug); gentamicin (Drug); amikacin (Drug); aztreonam (Drug); imipenem (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Northwestern University

Official(s) and/or principal investigator(s):
Anthony J Schaeffer, MD, Principal Investigator, Affiliation: Northwestern University

Overall contact:
Anthony J Schaeffer, MD, Phone: (312) 908-9844, Email: ajschaeffer@northwestern.edu

This study is being conducted in men scheduled to undergo transrectal ultrasound-guided prostate biopsy (TRUSP). Traditionally prior to prostate biopsy, an antibiotic, ciprofloxacin, has been given to men to prevent biopsy-related infections. In recent years as ciprofloxacin resistance has increased in the community, more and more men are becoming infected with ciprofloxacin-resistant bacteria after prostate biopsy. This study is being done to determine if obtaining rectal swab cultures and choosing antibiotics based on these culture results will result in fewer infectious complications than giving all men ciprofloxacin. The investigators will compare 2 groups: men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy, and men whose swabs do show ciprofloxacin-resistant bacteria will receive alternative antibiotics based on their culture results. Our hypothesis is that these 2 groups will have equal numbers of post-biopsy infectious complications and both groups will have fewer infectious complications than a historical group who received empiric ciprofloxacin without the benefit of rectal swab culture results.

Official title: Evaluation of Directed Antimicrobial Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy (TRUSP)

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Infection rates

Secondary outcome:

Infection rate

Demographics and medical co-morbidities

Genus and species of rectal swab isolates with their antibiotic susceptibility profiles

Detailed description: This study is a prospective, nonrandomized trial evaluating the efficacy of directed antimicrobial prophylaxis prior to transrectal ultrasound-guided prostate biopsy (TRUSP) compared with ciprofloxacin prophylaxis, the current standard of care. Northwestern University will be the lead site. After signing informed consent, study participants will complete a pre-biopsy questionnaire to record demographics and assess for known risk factors for infection and will have a rectal swab obtained. Patients whose swabs indicate colonization with ciprofloxacin-susceptible gram-negative bacteria (CS-GNB) will receive ciprofloxacin as pre-procedure prophylaxis and those whose swabs indicate colonization with ciprofloxacin-resistant gram-negative bacteria (CR-GNB) will receive pre-procedure antimicrobial prophylaxis based on study protocol. All patients will be contacted by phone twice after their biopsies, at approximately 7 and 30 days, to detail post-procedure infectious complications including fever, urinary tract infection, bacteremia and sepsis. Subjects who experience infections will have additional information regarding the infectious complications and cost of therapy abstracted from their medical record. The TRUSP results will also be recorded. Bacterial isolates from the rectal swabs will be archived.

Minimum age: 30 Years. Maximum age: 90 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Ability and willingness to provide written informed consent.

- All individuals who will undergo TRUSP as part of their standard of care are eligible

for study. Exclusion Criteria:

- Men under 30 years of age

- Individuals whose rectal swab indicates that they harbor CS-GNB who cannot receive

ciprofloxacin as pre-procedure prophylaxis for any reason

- Individuals whose rectal swab indicates that they harbor CR-GNB who cannot abide by

the antimicrobial prophylaxis guidelines outlined in the study protocol for any reason

- Individuals who do not wish to complete the pre-procedure risk factor questionnaire

or the two post-procedure phone questionnaires to assess for infectious complications

Anthony J Schaeffer, MD, Phone: (312) 908-9844, Email: ajschaeffer@northwestern.edu

Northwestern University Department of Urology, Chicago, Illinois 60611, United States; Recruiting
Anthony J Schaeffer, MD, Phone: 312-908-1615, Email: ajschaeffer@northwestern.edu
Teresa R Zembower, MD, Phone: (312) 926-8358, Email: t-zembower@northwestern.edu

Starting date: August 2012
Last updated: March 27, 2015